References
- Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
- Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevaci-zumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905.
- Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa2200015.
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gem-citabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81.
- Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3(4):386-401.
- Gujarathi R, Peshin S, Zhang X, et al. Intrahepatic cholangio-carcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatol Commun. 2025;9(7):e0743.
- Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma. 2014;1:115-125.
- Moeini A, Sia D, Bardeesy N, et al. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291-300.
- Hussain MM, Wang JM, Zhai AQ, et al. Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis. World J Gastrointest Oncol. 2025;17(7):107995.
- Kudo M, Finn RS, Galle PR, et al. IMbrave150: Enjcacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2023;12(3):236-249.
- Tian T, Guo J, Hu JL, et al. Advanced hepatocellular carcinoma and palliative care: a scoping review. BMJ Support Palliat Care. 2024;14(2):163-170.
- Merath K, Tiwari A, Parikh AA, Pawlik TM. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol. 2023;19(39):2607-2621.
- Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3:337–348.
- Yoo C, Hyung J. Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma. Liver Cancer. 2023;13(2):119-135.
- Primary Malignant Tumours of the Liver: Evidence Mapping for Hepatocellular Carcinoma and Intrahepatic Cholangiocar-cinoma.
- Mihaylov V, Joncheva M, Grigorov E, Saltchev P. Enhanced recovery after surgery in hepatobiliary surgery. Bulgarian Journal of Public Health. 2020;12(2):35-53.
- Singal AG, Llovet JM, Yarchoan M, et al. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology. 2021;160(8):2572-2584.